CN119139329A - 布林西多福韦的制剂 - Google Patents
布林西多福韦的制剂 Download PDFInfo
- Publication number
- CN119139329A CN119139329A CN202411127002.7A CN202411127002A CN119139329A CN 119139329 A CN119139329 A CN 119139329A CN 202411127002 A CN202411127002 A CN 202411127002A CN 119139329 A CN119139329 A CN 119139329A
- Authority
- CN
- China
- Prior art keywords
- brinzdofovir
- concentration
- dose
- administration
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355844P | 2016-06-28 | 2016-06-28 | |
| US62/355,844 | 2016-06-28 | ||
| US201662394665P | 2016-09-14 | 2016-09-14 | |
| US62/394,665 | 2016-09-14 | ||
| US201762446213P | 2017-01-13 | 2017-01-13 | |
| US62/446,213 | 2017-01-13 | ||
| US201762465053P | 2017-02-28 | 2017-02-28 | |
| US62/465,053 | 2017-02-28 | ||
| US201762507397P | 2017-05-17 | 2017-05-17 | |
| US62/507,397 | 2017-05-17 | ||
| US201762512825P | 2017-05-31 | 2017-05-31 | |
| US62/512,825 | 2017-05-31 | ||
| CN201780040478.9A CN109475497A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| PCT/US2017/039804 WO2018005676A1 (en) | 2016-06-28 | 2017-06-28 | Formulations of brincidofovir |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780040478.9A Division CN109475497A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119139329A true CN119139329A (zh) | 2024-12-17 |
Family
ID=59313330
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411127002.7A Pending CN119139329A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| CN202210134248.1A Pending CN114569547A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| CN201780040478.9A Pending CN109475497A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| CN202410393564.XA Pending CN118416082A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210134248.1A Pending CN114569547A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| CN201780040478.9A Pending CN109475497A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
| CN202410393564.XA Pending CN118416082A (zh) | 2016-06-28 | 2017-06-28 | 布林西多福韦的制剂 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170368082A1 (https=) |
| EP (2) | EP4295853A3 (https=) |
| JP (3) | JP6878473B2 (https=) |
| CN (4) | CN119139329A (https=) |
| AU (2) | AU2017290703B2 (https=) |
| DK (1) | DK3474822T3 (https=) |
| ES (1) | ES3037596T3 (https=) |
| FI (1) | FI3474822T3 (https=) |
| PL (1) | PL3474822T3 (https=) |
| PT (1) | PT3474822T (https=) |
| WO (1) | WO2018005676A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2999476T3 (en) | 2013-11-15 | 2018-09-03 | Chimerix Inc | MORPHIC FORMS OF HEXADECYLOXYPROPYL PHOSPHONATE TESTERS |
| EP4295853A3 (en) * | 2016-06-28 | 2024-03-06 | Emergent BioDefense Operations Lansing LLC | Formulations of brincidofovir |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN114073772A (zh) * | 2020-08-18 | 2022-02-22 | 上海市公共卫生临床中心 | 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途 |
| CN114558022B (zh) * | 2022-02-16 | 2023-11-17 | 华中农业大学 | 布林西多福韦在制备抗伪狂犬病毒药物中的应用 |
| CN114732821A (zh) * | 2022-04-24 | 2022-07-12 | 华中农业大学 | 西多福韦的前药在制备防治非洲猪瘟药物中的应用 |
| JP7417339B1 (ja) | 2023-08-07 | 2024-01-18 | シンバイオ製薬株式会社 | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 |
| WO2025072782A1 (en) * | 2023-09-29 | 2025-04-03 | Symbio Pharmaceuticals Limited | Brincidofovir for treatment of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60038038T2 (de) | 1999-12-03 | 2009-02-12 | The Regents of The University of California at San Diego, La Jolla | Phosphonatverbindungen |
| JP4136340B2 (ja) * | 2000-08-18 | 2008-08-20 | 武田薬品工業株式会社 | 注射剤 |
| JP2008538354A (ja) | 2005-04-08 | 2008-10-23 | キメリクス，インコーポレイテッド | ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法 |
| JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| WO2008133966A1 (en) * | 2007-04-27 | 2008-11-06 | Chimerix, Inc. | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
| JP2011116658A (ja) * | 2008-03-13 | 2011-06-16 | Chemo-Sero-Therapeutic Research Inst | 豚萎縮性鼻炎用薬剤の製造方法 |
| US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| WO2011017253A1 (en) | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| WO2011053812A1 (en) | 2009-10-30 | 2011-05-05 | Chimerix, Inc. | Methods of treating viral associated diseases |
| PT2508170E (pt) | 2009-12-03 | 2015-10-16 | Shanghai Hengrui Pharm Co Ltd | Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação |
| US20110263536A1 (en) | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
| ES2604137T3 (es) | 2010-08-31 | 2017-03-03 | Chimerix, Inc. | Derivados de éster de fosfonato y métodos de síntesis de los mismos |
| WO2013063436A1 (en) * | 2011-10-26 | 2013-05-02 | Chimerix, Inc. | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| WO2013163509A1 (en) | 2012-04-27 | 2013-10-31 | Chimerix, Inc. | A method of mitigating virus associated end-organ damage |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| DK2999476T3 (en) * | 2013-11-15 | 2018-09-03 | Chimerix Inc | MORPHIC FORMS OF HEXADECYLOXYPROPYL PHOSPHONATE TESTERS |
| EP4295853A3 (en) * | 2016-06-28 | 2024-03-06 | Emergent BioDefense Operations Lansing LLC | Formulations of brincidofovir |
-
2017
- 2017-06-28 EP EP23195544.4A patent/EP4295853A3/en active Pending
- 2017-06-28 PL PL17737695.1T patent/PL3474822T3/pl unknown
- 2017-06-28 WO PCT/US2017/039804 patent/WO2018005676A1/en not_active Ceased
- 2017-06-28 PT PT177376951T patent/PT3474822T/pt unknown
- 2017-06-28 DK DK17737695.1T patent/DK3474822T3/da active
- 2017-06-28 JP JP2018568195A patent/JP6878473B2/ja active Active
- 2017-06-28 AU AU2017290703A patent/AU2017290703B2/en active Active
- 2017-06-28 CN CN202411127002.7A patent/CN119139329A/zh active Pending
- 2017-06-28 CN CN202210134248.1A patent/CN114569547A/zh active Pending
- 2017-06-28 CN CN201780040478.9A patent/CN109475497A/zh active Pending
- 2017-06-28 ES ES17737695T patent/ES3037596T3/es active Active
- 2017-06-28 CN CN202410393564.XA patent/CN118416082A/zh active Pending
- 2017-06-28 EP EP17737695.1A patent/EP3474822B1/en active Active
- 2017-06-28 FI FIEP17737695.1T patent/FI3474822T3/fi active
- 2017-06-28 US US15/636,393 patent/US20170368082A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/722,699 patent/US20200138835A1/en not_active Abandoned
-
2021
- 2021-04-28 JP JP2021075612A patent/JP7221485B2/ja active Active
-
2022
- 2022-07-25 US US17/872,921 patent/US12485131B2/en active Active
-
2023
- 2023-01-18 JP JP2023005643A patent/JP7407984B2/ja active Active
- 2023-06-28 AU AU2023204117A patent/AU2023204117B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023033538A (ja) | 2023-03-10 |
| JP2019519570A (ja) | 2019-07-11 |
| DK3474822T3 (da) | 2025-08-18 |
| CN114569547A (zh) | 2022-06-03 |
| FI3474822T3 (fi) | 2025-08-15 |
| JP7221485B2 (ja) | 2023-02-14 |
| JP6878473B2 (ja) | 2021-05-26 |
| EP4295853A2 (en) | 2023-12-27 |
| US20230210873A1 (en) | 2023-07-06 |
| EP3474822A1 (en) | 2019-05-01 |
| EP4295853A3 (en) | 2024-03-06 |
| AU2023204117B2 (en) | 2025-03-20 |
| EP3474822B1 (en) | 2025-07-09 |
| AU2023204117A1 (en) | 2023-07-13 |
| JP7407984B2 (ja) | 2024-01-04 |
| AU2017290703A1 (en) | 2018-12-13 |
| CN118416082A (zh) | 2024-08-02 |
| CA3024886A1 (en) | 2018-01-04 |
| WO2018005676A1 (en) | 2018-01-04 |
| US20170368082A1 (en) | 2017-12-28 |
| PL3474822T3 (pl) | 2025-11-03 |
| ES3037596T3 (en) | 2025-10-03 |
| US20200138835A1 (en) | 2020-05-07 |
| CN109475497A (zh) | 2019-03-15 |
| US12485131B2 (en) | 2025-12-02 |
| JP2021143178A (ja) | 2021-09-24 |
| PT3474822T (pt) | 2025-08-21 |
| AU2017290703B2 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7221485B2 (ja) | ブリンシドフォビルの製剤 | |
| JP2024045290A (ja) | ベンダムスチンの製剤 | |
| HK40075964A (en) | Formulations of brincidofovir | |
| HK40115807A (zh) | 布林西多福韦的制剂 | |
| HK40120600A (zh) | 布林西多福韦的制剂 | |
| HK40105712A (en) | Formulations of brincidofovir | |
| CA3024886C (en) | Formulations of brincidofovir | |
| HK40005624A (en) | Formulations of brincidofovir | |
| HK40005624B (en) | Formulations of brincidofovir | |
| WO2020049521A1 (en) | Medroxyprogesterone acetate injectable compositions and methods of use | |
| KR20150030761A (ko) | 화합물 1-(6-｛[6-(4-플루오로페닐)[1,2,4]트리아졸로[4,3-b]피리다진-3-일]술파닐｝-1,3-벤조티아졸-2-일)-3-(2-모르폴린-4-일에틸)우레아를 포함하는 항종양 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40120600 Country of ref document: HK |